

## HR 3927

MADE in America Act

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Jun 16, 2021

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Jun 17, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/3927>

### Sponsor

**Name:** Rep. Carter, Earl L. "Buddy" [R-GA-1]

**Party:** Republican • **State:** GA • **Chamber:** House

### Cosponsors (14 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cartwright, Matt [D-PA-8]	D · PA		Jun 16, 2021
Rep. Crawford, Eric A. "Rick" [R-AR-1]	R · AR		Jun 16, 2021
Rep. Griffith, H. Morgan [R-VA-9]	R · VA		Jun 16, 2021
Rep. McKinley, David B. [R-WV-1]	R · WV		Jun 16, 2021
Rep. Rice, Tom [R-SC-7]	R · SC		Jun 16, 2021
Rep. Soto, Darren [D-FL-9]	D · FL		Jun 16, 2021
Rep. Van Drew, Jefferson [R-NJ-2]	R · NJ		Jun 16, 2021
Rep. Westerman, Bruce [R-AR-4]	R · AR		Jun 16, 2021
Rep. Balderson, Troy [R-OH-12]	R · OH		Dec 2, 2021
Rep. Katko, John [R-NY-24]	R · NY		Dec 2, 2021
Rep. Hudson, Richard [R-NC-8]	R · NC		Mar 15, 2022
Rep. Jackson, Ronny [R-TX-13]	R · TX		Mar 15, 2022
Rep. Mullin, Markwayne [R-OK-2]	R · OK		Mar 24, 2022
Rep. Dunn, Neal P. [R-FL-2]	R · FL		May 10, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 17, 2021
Ways and Means Committee	House	Referred To	Jun 16, 2021

### Subjects & Policy Tags

**Policy Area:**

Health

## Related Bills

Bill	Relationship	Last Action
117 S 2082	Identical bill	<b>Jun 16, 2021:</b> Read twice and referred to the Committee on Finance.

## Summary (as of Jun 16, 2021)

### Manufacturing API, Drugs, and Excipients in America Act or the MADE in America Act

This bill establishes a tax credit for taxpayers engaged in medical production activities in certain areas and contains other provisions related to pharmaceuticals.

An eligible taxpayer may claim a tax credit equal to 25% of qualified expenditures related to the production of pharmaceuticals, medical devices, or other related items in a designated qualified opportunity zone with a poverty rate higher than 30%. The bill provides for increases to this tax credit in certain situations, such as if a substantial portion of the employees reside in areas with certain poverty levels.

In addition, the Food and Drug Administration (FDA) must continue programs to facilitate the development and review of new drug or biological products that are manufactured using certain advanced manufacturing technologies. The bill imposes various requirements on these programs, including deadlines for evaluating such a technology.

Furthermore, the Department of Health and Human Services must ensure timely and effective internal coordination and alignment between FDA field investigators and the staff of the Center for Drug Evaluation and Research's Office of Compliance and Drug Shortage Program regarding reports and feedback related to facility inspections.

## Actions Timeline

- **Jun 17, 2021:** Referred to the Subcommittee on Health.
- **Jun 16, 2021:** Introduced in House
- **Jun 16, 2021:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.